Expression of Cytokeratin 19 (CK19) and Vascular Endothelial Growth Factor (VEGF) Genes in Peripheral Blood of Patients with Oral Squamous Cell Carcinoma (OSCC)

Document Type : Original Article (s)

Authors

1 Department of Cellular and Molecular Biology, School of Advanced Science and Technology, Tehran Medical Branch, Islamic Azad University, Tehran, Iran

2 Assistant Professor, Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD) AND Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3 Assistant Professor, Department of Cellular and Molecular Biology, School of Advanced Science and Technology, Tehran Medical Branch, Islamic Azad University, Tehran, Iran

4 Assistant Professor, Craniomaxillofacial Research Center AND Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: Oral squamous cell carcinoma (OSCC) is one of the 10 most common malignant tumors. This study aimed to evaluate the relevance of vascular endothelial growth factor (VEGF) and cytokeratin 19 (CK19) genes as biomarkers for diagnosis of OSCC.Methods: In this study, 30 patients and 30 healthy individuals were selected. CK19 and VEGF were measured in peripheral blood using real-time polymerase chain reaction (PCR) technique. T-test was performed to analyze the data.Findings: In patients with OSCC, CK19 and VEGF markers were positive in 17 and 23 patients out of 30.Conclusion: The expression of VEGF and CK19 is more among the patients with OSCC, compared to healthy people. In summary, the result of this study can be considered as a diagnostic screening test in the early stages of the disease.

Keywords

References

  1. Wong YK, Tsai WC, Lin JC, Poon CK, Chao SY, Hsiao YL, et al. Socio-demographic factors in the prognosis of oral cancer patients. Oral Oncol 2006; 42(9): 893-906.
  2. Pourhoseingholi MA, Faghihzadeh S, Hajizadeh E, Abadi A. Years of life lost due to colorectal cancer in Iran. Gastroenterol Hepatol Bed Bench 2010; 3(4): 187-9.
  3. Wunsch-Filho V. The epidemiology of oral and pharynx cancer in Brazil. Oral Oncol 2002; 38(8): 737-46.
  4. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009; 45(4-5): 309-16.
  5. Salehi Nodeh A, Ghafouri S, Razavi S, Mirshafie S. Assessment of TPS tumor marker with ELISA for early detection and monitoring of Breast Cancer. Payavard Salamat 2008; 2(1-2): 84-8. [In Persian].
  6. Boonstra JJ, Kok TC, Wijnhoven BP, van Heijl M, van Berge Henegouwen MI, Ten Kate FJ, et al. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer 2011; 11: 181.
  7. Xu F, Chen J, Shen HH, Wang XD, Shan J. The diagnostic significance of the detection of cytokeratin 19 mRNA by quantitative RT-PCR in benign and malignant pleural effusions. J Zhejiang Univ Sci 2004; 5(10): 1286-9.
  8. Prapulla DV, Sujatha PB, Pradeep AR. Gingival crevicular fluid VEGF levels in periodontal health and disease. J Periodontol 2007; 78(9): 1783-7.
  9. Kim HY, Park SY, Lee SW, Lee HR, Lee WS, Rhim BY, et al. Inhibition of HMGB1-induced angiogenesis by cilostazol via SIRT1 activation in synovial fibroblasts from rheumatoid arthritis. PLoS One 2014; 9(8): e104743.
  10. Marocchio LS, Lima J, Sperandio FF, Correa L, de Sousa SO. Oral squamous cell carcinoma: An analysis of 1,564 cases showing advances in early detection. J Oral Sci 2010; 52(2): 267-73.
  11. Maleki D, Ghojazadeh M, Mahmoudi SS, Mahmoudi SM, Pournaghi-Azar F, Torab A, et al. Epidemiology of oral cancer in Iran: A systematic review. Asian Pac J Cancer Prev 2015; 16(13): 5427-32.
  12. Lippman SM, Sudbo J, Hong WK. Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol 2005; 23(2): 346-56.
  13. Umeda M, Shigeta T, Takahashi H, Minamikawa T, Komatsubara H, Oguni A, et al. Clinical evaluation of Lugol's iodine staining in the treatment of stage I-II squamous cell carcinoma of the tongue. Int J Oral Maxillofac Surg 2011; 40(6): 593-6.
  14. De Roock W, Biesmans B, De Schutter J, Tejpar S. Clinical biomarkers in oncology: focus on colorectal cancer. Mol Diagn Ther 2009; 13(2): 103-14.
  15. Kashani K, Bahrami N, Barikro N, Mohamadnia A. A pilot study of CK20 mRNA, VEGF mRNA, VEGF protein in the peripheral blood of patients with non-small cell lung cancer. Minerva Pneumol 2017; 56: 229-34.
  16. Payehghadr S, Bahrami N, Naji T, Mohammadi F. Detection of miR-21, MUC1mRNA and VEGF protein biomarkers expression changes in oral squamous cell carcinomas (OSCC) in peripheral blood. Asian Pacific Journal of Cancer Biology 2018; 3(2): 59-64.
  17. Guo Y, Wang J, Huang P. Clinical significance of CK20, CK19, CEA mRNAs in peripheral blood from lung cancer patients. Zhongguo Fei Ai Za Zhi 2009; 12(9): 1013-7. [In Chinese].
Journal of Isfahan Medical School
Volume 37, Issue 526 - Serial Number 526
March and April 2019
Pages 480-484

Files

History

  • Receive Date: 24 May 2019
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics